TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1980415
Drug: Chlorphenaethazin (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorphenaethazin (1.0 mg/kg)
Study: 6992760
Drug: Initial treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial treatment factors (sex, social class, optimism about therapist)
Study: 6992760
Drug: Degree of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Degree of improvement during treatment
Study: 25328079
Drug: Sitagliptin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin (50 mg)
Study: 25328079
Drug: Metformin (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (750 mg)
Study: 24942407
Drug: Cilostazol (100mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilostazol (100mg twice daily)
Study: 21147691
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid (ZA) 4 mg intravenous every 3 months
Study: 17991545
Drug: Bicalutamide (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bicalutamide (150 mg/day for 120 days) plus surgery
Study: 16296363
Drug: Midazolam 0.04‐0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 0.04‐0.05 mg x kg(‐1)
Study: 11911994
Drug: Glyceryltrinitrate (GTN)
Normalized name: GTN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glyceryltrinitrate (GTN) + Capsaicin cream
Study: 11911994
Drug: Capsaicin cream
Normalized name: CAPSAICIN 0.1 g in 100 g TOPICAL CREAM [Capsaicin Cream]
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Capsaicin cream alone
Study: 31160237
Drug: Carfilzomib (56
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carfilzomib (56 mg/m2) and Dexamethasone (Kd56)
Study: 28973620
Drug: Clinically guided
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinically guided warfarin dosing
Study: 23537721
Drug: rIX-FP (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: rIX-FP (25 IU/kg) on-demand therapy for 20 weeks
Study: 23537721
Drug: rIX-FP (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: rIX-FP (25 IU/kg) weekly prophylaxis for up to 44 weeks
Study: 19950570
Drug: TAM sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAM sequential (TAM_SEQ)
Study: 19950570
Drug: TAM concurrent
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAM concurrent (TAM_CON)
Study: 19950570
Drug: AI sequential
Normalized name: AI-128
DrugBank: AI-128 (DB05841)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AI sequential (AI_SEQ)
Study: 19950570
Drug: AI concurrent
Normalized name: AI-128
DrugBank: AI-128 (DB05841)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AI concurrent (AI_CON)
Study: 17300863
Drug: Interferon-beta(1a) (Rebif,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon-beta(1a) (Rebif, Serono) subcutaneous injections three times a week (group A)
Study: 17300863
Drug: Not receiving
Approvals — FDA: no, EMA: no, PMDA: no
Description: Not receiving disease-modifying treatment (group B)
Study: 8857018
Drug: Interleukin-2 plus
Normalized name: Interleukin-2 aldesleukin
DrugBank: Aldesleukin (DB00041)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interleukin-2 plus antiretroviral therapy
Study: 1298048
Drug: Repeated injections
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated injections of ranitidine, 50 mg every 6 h (group A)
Study: 1298048
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of ranitidine, 50-mg bolus followed by 0.125 mg/kg/h (group B)
Study: 6326014
Drug: Lonidamine in
Normalized name: lonidamine
DrugBank: Lonidamine (DB06266)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lonidamine in combination with other anticancer agents
Study: 31145689
Drug: Curcumin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin (500 mg) with piperine (5 mg)
Study: 18488813
Drug: Adcef Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adcef Suspension (125 mg/5 ml cefdinir)
Study: 18488813
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation (125 mg/5 ml cefdinir)
Study: 17109346
Drug: Attenuated rotavirus
Normalized name: Live attenuated Rotavirus Ag
Approvals — FDA: no, EMA: no, PMDA: no
Description: Attenuated rotavirus vaccine candidate 89-12
Study: 17109346
Drug: Rotarix vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rotarix vaccine developed from attenuated 89-12
Study: 15235312
Drug: Valtrex treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valtrex treatment
Study: 11765590
Drug: lysine clonixinate
Normalized name: lysine clonixinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: lysine clonixinate (125 mg five times a day for 3 days before and 13 days after ingestion of a single dose of phenprocoumon)
Study: 11765590
Drug: phenprocoumon (18
Approvals — FDA: no, EMA: no, PMDA: no
Description: phenprocoumon (18 mg)
Study: 29436564
Drug: Celery leaf
Normalized name: CELERY LEAF PWDR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celery leaf extract (250 mg, 3 times per day for 12 days)
Study: 23389964
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) for OCD
Study: 20613468
Drug: Propofol (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (6 microg/ml) via plasma target‐controlled infusion using the Schnider model
Study: 16704094
Drug: 1.1% sodium
Normalized name: Neutral 1.1% Sodium Fluoride Dental Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.1% sodium fluoride and acidulated phosphate gel
Study: 26004421
Drug: CIRCuiTS (Computerized
Approvals — FDA: no, EMA: no, PMDA: no
Description: CIRCuiTS (Computerized Cognitive Remediation Therapy Programme)
Study: 22759830
Drug: Autologous platelet-rich
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous platelet-rich plasma eyedrops along with standard medical treatment
Study: 20096936
Drug: Olanzapine (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (15 mg QD on day 1, 5-20mg QD thereafter)
Study: 12558710
Drug: Subcutaneous (SC)
Normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous (SC) rehydration
Study: 12558710
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) rehydration
Study: 10677386
Drug: C-peptide infusion
Normalized name: peptide-T
DrugBank: Peptide-T (DB19279)
Approvals — FDA: no, EMA: no, PMDA: no
Description: C-peptide infusion at 3 pmol.min(‐1).kg(‐1) for 60 min and then at 10 pmol.min(‐1).kg(‐1) for 60 min
Study: 8931848
Drug: Bunazosin retard
Normalized name: bunazosin
DrugBank: Bunazosin (DB12230)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bunazosin retard (12 mg)
Study: 8931848
Drug: Prazosin retard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prazosin retard (4 mg)
Study: 3893286
Drug: Local treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local treatment plus thymostimulin
Study: 3893286
Drug: Local treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local treatment plus placebo (control group)
Study: 31388739
Drug: Spirulina (4.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spirulina (4.8 g daily for 17 days)
Study: 31388739
Drug: Wakame (4.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wakame (4.8 g daily for 17 days)
Study: 28002316
Drug: Oral pregabalin
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral pregabalin 150 mg and intravenous normal saline (group HP)
Study: 28002316
Drug: Intravenous lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous lidocaine 40 mg (group L)
Study: 28002316
Drug: Oral pregabalin
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral pregabalin 75 mg and intravenous normal saline (group LP)
Study: 24231639
Drug: High protein
Normalized name: Vital High Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: High protein intake (≥ 4.6 g · kg(‐1) · day(‐1))
Study: 24231639
Drug: Average protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Average protein intake of 4.3 ± 0.4 g · kg(‐1) · day(‐1)
Study: 24231639
Drug: High protein
Normalized name: Vital High Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: High protein group (4.6 to 5.5 g · kg(‐1) · day(‐1), n = 16)
Study: 23326930
Drug: Test treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test treatment (nutriological combination of vitamins, trace elements, and phytochemicals)
Study: 20615100
Drug: GLIM +
Normalized name: Glimepiride
DrugBank: Glimepiride (DB00222)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GLIM + PIO combination (up-titration 2 mg + 30 mg/4 mg + 30 mg/4 mg + 4 mg)
Study: 20615100
Drug: GLIM (up-titration
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLIM (up-titration 4/5/6 mg)
Study: 15723969
Drug: Candesartan (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan (8 to 16 mg per day)
Study: 15723969
Drug: Enalapril (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (10 to 20 mg per day)
Study: 10740903
Drug: DHE focused
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHE focused on oral hygiene instruction (OHI) using fluoride toothpaste
Study: 9690309
Drug: Chemotherapy containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy containing platinum
Study: 9690309
Drug: Chemotherapy using
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy using alkylating agents
Study: 9690309
Drug: Chemotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy with Cisplatin
Study: 9690309
Drug: Concomitant radiotherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concomitant radiotherapy and chemotherapy using 5-Fluoro-uracil, VP16, and platinum
Study: 9690309
Drug: Short initial
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short initial chemotherapy or concomitant therapy
Study: 9690309
Drug: Short neoadjuvant
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short neoadjuvant chemotherapy to surgery
Study: 2345633
Drug: Silymarin (Legalon)
Normalized name: silymarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silymarin (Legalon) therapy at a daily dose of 420 mg for six months
Study: 6303490
Drug: Cefoxitin 2
Normalized name: cefoxitin 2000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefoxitin 2 g intramuscularly with oral probenecid 1 g
Study: 26803355
Drug: Exenatide supplementation
Normalized name: Exenatide
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exenatide supplementation on glargine insulin (group B)
Study: 26803355
Drug: Intense, self-regulated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intense, self-regulated insulin therapy alone (group C)
Study: 22080870
Drug: Metacognitive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metacognitive therapy (MCT), 8 weekly intervention sessions
Study: 20411995
Drug: Pharmacists provided
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacists provided intensified hypertension management and drug adherence counseling
Study: 15966377
Drug: Epidural tramadol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural tramadol infusion
Study: 15966377
Drug: Intravenous tramadol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous tramadol infusion
Study: 12651051
Drug: Acute hyperglycemia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute hyperglycemia (13.9 mmol/l, 250 mg/dl)
Study: 12651051
Drug: Euglycemia (5.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Euglycemia (5.5 mmol/l, 100 mg/dl)
Study: 31491932
Drug: Exercise +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise + Learning (E + L)
Study: 31491932
Drug: Learning Only
Approvals — FDA: no, EMA: no, PMDA: no
Description: Learning Only (L)
Study: 29174765
Drug: Attention Control
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Attention Control Treatment (ACT)
Study: 12446070
Drug: Algorithm combining
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Algorithm combining basal volume flow <20 ml/min and graft flow reserve <2
Study: 10100178
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose E2/NETA (2 mg E2/1 mg NETA)
Study: 17530099
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose E2/NETA (1 mg E2/0.5 mg NETA)
Study: 8889353
Drug: Enalapril drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril drug regimen
Study: 8889353
Drug: Atenolol drug
Normalized name: Atenolol
DrugBank: Atenolol (DB00335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atenolol drug regimen
Study: 8889353
Drug: Amlodipine drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine drug regimen
Study: 7104149
Drug: metoprolol, 100-300
Approvals — FDA: no, EMA: no, PMDA: no
Description: metoprolol, 100-300 mg/day
Study: 7104149
Drug: pindolol, 5-15
Approvals — FDA: no, EMA: no, PMDA: no
Description: pindolol, 5-15 mg/day
Study: 30499837
Drug: Group MP
Normalized name: 6 MP
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Group MP (300 mg pregabalin orally + IV magnesium sulphate 50 mg/kg)
Study: 30499837
Drug: Group P
Normalized name: High mobility group protein HMGI-C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group P (300 mg pregabalin orally + IV placebo)
Study: 30499837
Drug: Group M
Normalized name: Coenzyme M
DrugBank: Coenzyme M (DB09110)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group M (IV magnesium sulphate 50 mg/kg + placebo capsule)
Study: 30499837
Drug: Group C
Normalized name: STREPTOCOCCUS ANTIGEN (GROUP C)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group C (placebo capsule + IV placebo)
Study: 30650288
Drug: Glucosamine, 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucosamine, 1 pill each time, 3 times per day for 3 months
Study: 26703477
Drug: Intra-articular facet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular facet joint injections with local anaesthetic and steroids
Study: 20022553
Drug: ZengShengPing (ZSP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZengShengPing (ZSP) - 4 tablets, 3 times per day for 8-12 months
Study: 18154900
Drug: Therapeutic hypothermia
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic hypothermia (head cooling for 72 hours starting within 6 hours of birth, rectal temperature maintained at 34.5 degrees C ± 0.5 degrees C)
Study: 10531164
Drug: Manual titrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual titrated nCPAP therapy
Study: 1989572
Drug: 10 mg/d
Normalized name: Arixtra 10 mg/dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/d of oral haloperidol
Study: 1989572
Drug: 30 mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/d of oral haloperidol
Study: 1989572
Drug: 80 mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg/d of oral haloperidol
Study: 6636033
Drug: 10 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g of fish oil (n-3 PUFA) for 4 weeks
Study: 6636033
Drug: 10 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g of vegetable oil (n-6 PUFA) for 4 weeks
Study: 30399034
Drug: CrAg screening
Normalized name: SUN PROTECTANTS/SCREENS,TOPICAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: CrAg screening and preemptive fluconazole therapy
Study: 30555398
Drug: Self-help book
Normalized name: loratadine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-help book for insomnia (cognitive behavioral therapy for insomnia)
Study: 25228440
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg lutein
Study: 25228440
Drug: lutein (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: lutein (10 mg) + zeaxanthin (10 mg)
Study: 19043656
Drug: Alendronate therapy
Normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alendronate therapy (with calcium 500 mg/day and cholecalciferol 250 IU/day)
Study: 11259687
Drug: Statin drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin drugs (HMG CoA reductase inhibitors)
Study: 1977438
Drug: Cicloprolol 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cicloprolol 50 mg day‐1 with digoxin 0.25 mg day‐1
Study: 1977438
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with digoxin 0.25 mg day‐1
Study: 318680
Drug: Dextroamphetamine (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextroamphetamine (15 mg)
Study: 318680
Drug: L-dopa (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-dopa (125 to 500 mg)
Study: 318680
Drug: Dextroamphetamine (after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextroamphetamine (after treatment with methylphenidate)
Study: 318680
Drug: Methylphenidate (after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate (after treatment)
Study: 23453011
Drug: Intensive glycemic
Normalized name: Glycerin
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive glycemic control (target blood glucose 120-160 mg/dl)
Study: 23453011
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (target blood glucose 161-200 mg/dl)
Study: 21557031
Drug: Delivery of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delivery of influenza vaccine
Study: 19234885
Drug: Celecoxib 200
Normalized name: celecoxib 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib 200 mg twice daily for 3 weeks
Study: 12742557
Drug: Low-dose COC
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose COC (20 microg EE and 75 microg GTD) - Group A
Study: 12742557
Drug: Ultra-low-dose COC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultra-low-dose COC (15 microg EE and 60 microg GTD) - Group B
Study: 8922571
Drug: Azithromycin 10
Normalized name: azithromycin 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin 10 mg/kg 1 x daily for 3 days
Study: 8922571
Drug: Azithromycin 20
Normalized name: azithromycin 20 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin 20 mg/kg 1 x daily for 3 days
Study: 8922571
Drug: Penicillin V
Normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Penicillin V 125-250 mg 4 x daily for 10 days
Study: 6690193
Drug: 99mTc‐labelled erythrocytes
Approvals — FDA: no, EMA: no, PMDA: no
Description: 99mTc‐labelled erythrocytes (IgG‐RBC) coated with Rhesus anti‐D antibody (high coating)
Study: 6690193
Drug: 99mTc‐labelled erythrocytes
Approvals — FDA: no, EMA: no, PMDA: no
Description: 99mTc‐labelled erythrocytes (IgG‐RBC) coated with Rhesus anti‐D antibody (low coating)
Study: 31706286
Drug: Herbal combination
Normalized name: HERBAL MISCELLANEOUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herbal combination (420 mg proprietary blend of Urox®)
Study: 12077544
Drug: 2% ketoconazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% ketoconazole + 0.05% desonide gel (n = 9)
Study: 12077544
Drug: Unmedicated gel
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unmedicated gel (placebo) (n = 9)
Study: 8541695
Drug: Structured-triglyceride (STG)
Normalized name: CAPRYLIC TRIGLYCERIDE
DrugBank: Tricaprylin (DB12176)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured-triglyceride (STG) emulsion (medium and high doses)
Study: 8541695
Drug: Fat infusion
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fat infusion (STG and LCT)
Study: 31812554
Drug: Pembrolizumab at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab at an initial dose of 2 mg/kg every 3 weeks
Study: 23379590
Drug: Lanthanum carbonate
Normalized name: Lanthanum Carbonate
DrugBank: Lanthanum carbonate (DB06792)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lanthanum carbonate (1500 mg-3000 mg)
Study: 18036080
Drug: Caffeine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (200 mg) administered every 2 hours each night for 4 administrations
Study: 8203435
Drug: Preoperative gonadotropin-releasing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative gonadotropin-releasing hormone agonist (leuprolide acetate) for 2 months
Study: 8203435
Drug: Preoperative gonadotropin-releasing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative gonadotropin-releasing hormone agonist (leuprolide acetate)
Study: 29203473
Drug: THR‐184 treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: THR‐184 treatment groups
Study: 20556561
Drug: Eprosartan 600
Normalized name: eprosartan 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eprosartan 600 mg + Hydrochlorothiazide 12.5 mg
Study: 15842137
Drug: Jianpi Huoxue
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jianpi Huoxue herbs (JPHXH) plus chemotherapy (CT)
Study: 10229292
Drug: Single drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single drug therapy (most commonly an ACE inhibitor)
Study: 1751272
Drug: Midazolam 0.1
Normalized name: midazolam 0.1 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 0.1 mg kg‐1 followed by fentanyl 2 micrograms kg‐1
Study: 6936524
Drug: Hydrocodone-acetaminophen combination
Normalized name: Dolorex Forte (hydrocodone / acetaminophen) Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocodone-acetaminophen combination
Study: 6936524
Drug: Codeine-acetaminophen combination
Normalized name: acetaminophen / codeine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Codeine-acetaminophen combination
Study: 6936524
Drug: Codeine-APC combination
Normalized name: Codeine
DrugBank: Codeine (DB00318)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Codeine-APC combination
Study: 19541918
Drug: Individualized best
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individualized best conventional therapy (CONV)
Study: 14988688
Drug: Potent, selective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potent, selective inhibitor of type I 5 alpha-reductase used alone
Study: 14988688
Drug: Potent, selective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potent, selective inhibitor of type I 5 alpha-reductase in combination with systemic minocycline